LCPUFA's AND MATERNAL AND CHILD HEALTH -
NEW CONCEPTS / EMERGING RESEARCH
Sunday 27 June

  


The workshop will include two sessions. The morning will be an opportunity for investigators to present new data and the afternoon will specifically address non-neural effects of LCPUFAs in maternal and child health.

There will be drinks and dinner on the preceding Saturday evening and the workshop will conclude on Sunday afternoon in time for participants to attend the ISSFAL official opening at 1800 hours.

REGISTRATION
to include a delegate pack and lunch. To book, simply download the form opposite.

As part of your ISSFAL 2004 registration - GBP 100
(to claim this reduced rate your booking form must be returned along with your completed main ISSFAL registration)

To attend the workshop only - GBP 120

SUBMISSION OF ABSTRACTS FOR SHORT PRESENTATIONS:

DEADLINE FOR SUBMISSIONS - Friday 30 April 2004

The invitation to submit abstracts is to encourage presentations on emerging research relating to the topics identified in the workshop programme. The presentation will be 10 minutes with an additional 5 minutes for discussion.

  1. Abstracts should be prepared to fit within a box of dimensions 10cm wide by 13.5cm long. Text size should be 10 point only, single spaced, and font should be Times Roman or equivalent. The abstract should include:

    a. A title in UPPER CASE and not exceeding three lines.

    b. A list of authors and (brief) affiliations, not exceeding four lines.
    Authors with different affiliations should be indicated by superscript
    numbers.

    c. Up to 23 lines of text describing the research and results. In general this will be a maximum of 200 words.
  2. Abstracts must contain original material, not published or presented at any other international meeting prior to ISSFAL 2004. Abstracts must be submitted in English.
  3. When submitting, please specify whether you are willing to have a poster presentation if your oral presentation submission is not successful.
  4. Abstracts received after the closing date and not conforming to these guidelines will not be considered.
  5. Abstracts will be reviewed by the workshop committee and will be judged on emerging research relating to the topics identified in the Workshop programme. Abstracts on topics outside the immediate focus of the meeting are welcomed. Statements in the text such as "results will be discussed" should be avoided.
  6. Authors will be advised via email of the selection NO LATER than Friday 28 May.
  7. The preferred method of submission is by email, sent to Professor Stewart Forsyth - j.stewart.forsyth@tuht.scot.nhs.uk Abstracts should be sent as an attachment in Word or Wordperfect format, prepared as described above. Acknowledgement of receipt will be sent by email.

 

 

  
download booking form pdf
 download booking form word file
 
PROGRAMME:
09:00-09:30 Registration
09:30-10:45 Behaviour and Learning
Invited speaker – Professor Gerard Hornstra
Free communications
10:45–11:10 Coffee
11.15–12.30 Postnatal Depression
Invited speaker – Dr Joe Hibbeln
Free communications
12:30–13:30 Lunch
13:30–14:30 Immune Function
Invited speaker – Professor Philip Calder
Free communications
14:30–15:30 Vascular Function
Invited speaker – tbc
Free communications
15:30–15:50 Coffee
15:50–16:30 Invited Lecture
“Should children be routinely supplemented with cod liver oil?”
16:30 Close
 

JOINT BRITISH DIETETIC ASSOCIATION FORUM -
Tuesday 29 June


Omega-3 Fatty Acids and Human Health:
Perspectives for the 21st Century

REGISTRATION
to include a delegate pack and lunch

As part of your ISSFAL 2004 registration - GBP 30
(please complete this as part of your main ISSFAL registration)

To attend the forum only
BDA members - GBP 35 Non members - GBP 45
(complete the form opposite)

 
PROGRAMME:
1300

Registration and lunch

Co-Chairpersons:
Dr Bill Lands, USA
Dr Angela Madden, London Metropolitan University, UK

1400 OMEGA-3 FATTY ACIDS AND HUMAN HEALTH:
SETTING THE SCENE
Professor Andrew Sinclair, RMIT University,
Melbourne, Australia
1430 THE IMPORTANCE OF OMEGA-3 FATTY ACIDS IN MATERNAL AND CHILD HEALTH
Ms Judy More, Freelance Dietitian, London, UK
1500 OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR DISEASE
Ms Lee Hooper, University Dental Hospital of Manchester, UK
1530 Tea break
1550 OMEGA-3 FATTY ACIDS AND PSYCHIATRIC DISORDERS
Dr Iain Glen, The Ness Foundation, Scotland, UK
1620 INTERACTIVE SOFTWARE FOR INDIVIDUALISED FOOD CHOICES
Dr Bill Lands, USA
1630 Chaired Panel Discussion and questions from the floor
1700 Close
 
 
download booking form pdf download booking form word file
 
TECHNICAL WORKSHOP - Tuesday 29 June
Oil Quality Issues in the Manufacturing and Public
Consumption of Omega-3 Oils

REGISTRATION
to include a delegate pack and lunch

As part of your ISSFAL 2004 registration - GBP 30
(please complete this as part of your main ISSFAL registration)

To attend the workshop only - GBP 70
(complete the form opposite)
1300

Registration and Lunch

Chairpersons:
Dr Colin Barrow, Ocean Nutrition Canada,
Nova Scotia, CANADA
Roger Clemens, USC School of Pharmacy
1400 PCBS, DIOXINS AND HEAVY METALS IN OMEGA-3 OIL DERIVED FROM FISH OIL:
LEVELS AND METHODS OF MEASUREMENT
Roger Clemens, USC School of Pharmacy
1420 MEASUREMENT OF LIPID OXIDATION FOR OMEGA-3 OILS
Fred Van de Voort, McGill IR Group
1440 TRANS FATTY ACIDS IN PROCESSED FISH OILS: LEVELS AND METHODS OF MEASUREMENT
Jonathan Curtis, Ocean Nutrition Canada
1500 THE COUNCIL FOR RESPONSIBLE NUTRITION
OMEGA-3 MONOGRAPH
Bjorn Rene, CRN omega-3 working group
1530 Tea
1600 DEVELOPMENT OF USP MONOGRAPHS OF FISH OIL RICH IN OMEGA-3 FATTY ACIDS
Gabriel Giancaspro, Information and Standards Development
1620 TECHNOLOGICAL CHALLENGES IN APPLYING FISH OIL IN FUNCTIONAL FOODS
Charlotte Jacobsen, Danish Institute for Fisheries Research
1640 Round table discussion
1730 Close
 
 
download booking form pdf
download booking form word file
 
CLINICIANS WORKSHOP - Tuesday 29 June

 

please see workshop below entitled:
Assessing Coronary Heart Disease Risks with PUFA Biomarkers

 

SATELLITE MEETING
THE OMEGA-3 RESEARCH INSTITUTE - "ASSESING CORONARY
HEART DISEASE RISKS WITH PUFA BIOMARKERS" - Sunday 27 June


Supported by:

REGISTRATION
to include a delegate pack and lunch. To book, simply download the form opposite.

As part of your ISSFAL 2004 registration - GBP 80
(to claim this reduced rate your booking form must be returned along with your completed main ISSFAL registration)

To attend the workshop only - GBP 100

DEADLINE FOR ABSTRACT SUBMISSIONS – FRIDAY 21 MAY 2004

 

ORGANISING COMMITTEE AND PANEL MEMBERS:

• Andrew J. Sinclair, Ph.D., Workshop Chair, RMIT University, Melbourne, Victoria, Australia
• Christine Albert, M.D., M.P.H., Brigham and Women's Hospital and Harvard University Medical School, Cambridge, MA, U.S.A.
• William S. Harris, Ph.D., Mid America Heart Institute and University of Missouri-Kansas City, U.S.A.
• Clemens von Schacky, M.D., Medizinische Klinik, Klinikum Innenstadt, University of Munich, Germany
• Christine Williams, Ph.D., School of Food Biosciences, University of Reading, U.K.

Ex Officio Members
• Philip Calder, Professor, Institute of Human Nutrition, University of Southampton, U.K
• Robert Katz, Ph.D., Omega-3 Research Institute, Inc. Bethesda, Maryland, U.S.A.

Additional Panel Members:
• Robert G. Ackman, Ph.D., Dalhousie University, Halifax, Nova Scotia, Canada
• William E.M. Lands, Ph.D., Rockville, Maryland, U.S.A.
• Trevor A. Mori, Ph.D. University of Western Australia, Perth, Western Australia;
• Arthur Spector, M.D., University of Iowa, Iowa City, Iowa, U.S.A.
• Parveen Yaqoob, Ph.D., University of Reading, U.K.

Additional Speakers:
• Luigi Mondello, Ph.D. University of Messina, Italy
• Jonathan Curtis, Ph.D. Ocean Nutrition Canada, Bedford, Nova Scotia, Canada
• Norman Salem, Jr., Ph.D., NIAAA, NIH, Rockville, Maryland, U.S.A.

OBJECTIVES OF THE WORKSHOP ON ASSESSING CHD RISKS WITH PUFA BIOMARKERS:

1. To present to a scientific panel and an audience of involved professionals a series of PUFA-based biomarkers for assessing an individual's risk of developing coronary heart disease (CHD) or dying from sudden cardiac death (SCD).
2. To evaluate the preventive or therapeutic value of the presented biomarkers and to assess their appropriateness for broad-scale use by cardiologists and other medical practitioners to predict the probability of an individual's risk of SCD, onset of CHD and/or occurrence of a major, non-fatal coronary event.
3. To develop and recommend guidelines for lowering the risk of death from CHD with n-3 LC PUFA supplementation.

 
PROGRAMME:
Chairpersons: Andrew Sinclair & Bill Harris
0830-0900 Registration
0900-0910 WELCOME AND INTRODUCTION
0910-0940 CONVERTING A BIOMARKER INTO A RISK FACTOR
Christine Albert
0940-1010 CLASSIC AND EMERGING RISK FACTORS FOR CHD
Parveen Yaqoob
1010-1040 PUFA AND RISK FACTORS FOR CHD
Clemens von Schacky
1040-1110 Coffee

1110-1140

 

THE N-6:N-3 PROPORTIONS IN DIET AND TISSUES: CHD RISK MARKERS?
William Lands
1140-1210 RBC EPA+DHA: The Omega-3 Index
Bill Harris
1210-1230 OIL QUALITY AND QUALITY CONTROL
Robert Ackman
1230-1300 Discussion of the morning presentations
1300-1400 Lunch

Chairpersons: Clemens von Schacky & Christine Williams
1400-1510 HIGH THROUGHPUT ANALYSES FOR PLASMA AND RBC
Andrew Sinclair (5'), Luigi Mondello (15'), Jonathan Curtis (15'), Norman Salem, Jr., (10') and Discussions (20')
1510-1610 PRESENTATION AND DISCUSSION OF SUBMITTED ABSTRACTS
(7-8 minute presentations of relevant new information approved by the Organising Committee)
1610-1635 Break
1635-1730

Organised discussion of the issues presented with the objective of developing consensus towards one or more useful biomarkers for predicting risk of developing CHD and dying from CHD. Developing and recommending guidelines for lowering the risk of death from CHD with n-3 LC PUFA supplementation.

Discussion leaders: Andrew Sinclair and Christine Albert
17.30 Workshop concludes
 

SUBMISSION OF ABSTRACTS FOR SHORT PRESENTATIONS:

Criteria for selection:
Relevance to the aims of the workshop.Scientific content:
The abstract should contain new data on biomarkers of n-3 and/or n-6 status as it relates to risk for CHD.Review:
The abstracts will be reviewed by a subgroup of members of the organizing committee chaired by Andrew J. Sinclair, Ph.D.
Please submit your one page abstract by email to Dr. Sinclair, at andrew.sinclair@rmit.edu.au by Friday 21 May 2004

DEADLINE FOR ABSTRACT SUBMISSIONS – FRIDAY 21 MAY 2004

Justification and Timing of the workshop on Assessing Coronary Heart Disease Risks With PUFA Biomarkers:

There is heightened interest in the potential risk-reducing effects of long-chain (LC) omega-3 (n-3) polyunsaturated fatty acids (PUFA) in coronary heart disease (CHD). For example, the Office of Dietary Supplements of the National Institutes of Health, U.S.A. is in the process of performing an evidence-based review of the role of Omega-3 PUFA in CHD. The U.S. Food and Drug Administration is evaluating the physiological role of omega-3 PUFA in reducing risk of CHD. The role of n-3 long chain (LC) PUFAs eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) as anti-hypertriglyceridemic agents has been established. Similarly, there is emerging clinical evidence for positive, elevating effects of n-3 LC PUFA supplementation on HDL levels, on increasing particle size and therefore diminishing atherosclerotic effects of remnant lipoproteins and very low density lipoproteins, on reducing blood pressure and on their capacity to reduce the risk of lethal coronary fibrillations.

During the past few months, a new PUFA biomarker has been developed for the assessment of risk-reduction in CHD. The red blood cell (RBC) membrane Omega-3 Index or simply the Omega-3 Index assesses the total EPA+DHA content of RBC membrane as % of total fatty acids in the membrane. This biomarker provides ranges for an individual's risks of SCD and therefore CHD and proposes high, intermediate and low risk ranges by delineating highest risk range as <4% EPA+DHA, the intermediate risk range as 4-8 EPA+DHA% and the lowest risk range as 8-10% EPA+DHA. Thus, carefully raising a person's RBC Omega-3 Index value from 2% to about 10% EPA+DHA could lower the person's risk of SCD by about 50%. The RBC Omega-3 Index was developed by Drs. William S. Harris and Clemens von Schacky.

Given the above and that over the years the n-6/n-3 ratio as well as other LC PUFA ratios e.g., EPA : cholesterol have been promoted as a measure of CHD risk reduction, it is both timely and justified to present, discuss and evaluate all these markers as relevant and immediately utilizable in predicting the physiological outcomes of CHD and the lethal pathology that could ensue when omega-3 levels are low. Therefore, the objective of this workshop is to evaluate the evidence and recommend valid markers for assessing the risk of developing CHD or dying from it. Such markers could enable the cardiologist or other physician to prescribe the appropriate therapeutic intervention, i.e. supplementation with omega-3 fatty acids.

 

 
 
download booking form pdf
download booking form word file